MPNs | Clinical

Phlebotomy Requirements Diminished With Rusfertide for Polycythemia Vera

June 15, 2021

The hepcidin mimetic rusfertide is suggested to reduce the need for phlebotomy in patients with polycythemia vera, according to the results of the phase 2 PTG-300-04 trial presented during the European Hematology Association 2021 Virtual Congress.

Important Safety Data Evaluated in Meta-Analysis of Myelofibrosis

June 15, 2021

Jan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.

Cardiovascular Risk Management Requires Further Improvement for MPNs

June 14, 2021

A proportion of patients with myeloproliferative neoplasms were not prescribed medications needed for the management of comorbidities in the United Kingdom, a poster presented during the 2021 European Hematology Association Virtual Congress showed.

Transfusion Independence at 24 Weeks Linked to Improved OS on Momelotinib in Myelofibrosis

June 11, 2021

Subgroup analyses from the the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials show that achievement of transfusion independence by the 24th week of treatment is associated with an improvement in overall survival compared with continued transfusion dependence at that time point.